Emergent BioSolutions Inc
EBS6.020USD
+0.390+6.93%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
328.09MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Emergent BioSolutions Inc Unternehmen
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Unternehmensinformationen
BörsenkürzelEBS
Name des UnternehmensEmergent BioSolutions Inc
IPO-datumNov 15, 2006
CEOMr. Joseph C. (Joe) Papa
Anzahl der mitarbeiter900
WertpapierartOrdinary Share
GeschäftsjahresendeNov 15
Addresse300 Professional Dr
StadtGAITHERSBURG
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl20879
Telefon12406313200
Websitehttps://emergentbiosolutions.com/
BörsenkürzelEBS
IPO-datumNov 15, 2006
CEOMr. Joseph C. (Joe) Papa
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
201.49K
-1.34%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
121.47K
-1.02%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
118.86K
+40.74%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
85.27K
+67.63%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
201.49K
-1.34%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
121.47K
-1.02%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
118.86K
+40.74%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
MCM Product sales
156.60M
70.48%
Commercial Product sales
45.30M
20.39%
Contracts and grants
20.30M
9.14%
Nach RegionUSD
Name
Umsatz
Anteil
Non-U.S Government
143.40M
64.54%
U.S.Government
78.80M
35.46%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
MCM Product sales
156.60M
70.48%
Commercial Product sales
45.30M
20.39%
Contracts and grants
20.30M
9.14%
Aktionärsstatistik
Aktualisiert: Thu, May 22
Aktualisiert: Thu, May 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.92%
Millennium Management LLC
4.61%
American Century Investment Management, Inc.
4.23%
State Street Global Advisors (US)
3.15%
Dimensional Fund Advisors, L.P.
2.94%
Other
79.14%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.92%
Millennium Management LLC
4.61%
American Century Investment Management, Inc.
4.23%
State Street Global Advisors (US)
3.15%
Dimensional Fund Advisors, L.P.
2.94%
Other
79.14%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
26.89%
Investment Advisor/Hedge Fund
20.51%
Hedge Fund
14.34%
Research Firm
4.30%
Individual Investor
3.04%
Pension Fund
1.04%
Bank and Trust
0.67%
Sovereign Wealth Fund
0.17%
Venture Capital
0.16%
Other
28.88%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
443
38.62M
71.16%
-7.77M
2025Q1
472
38.22M
70.45%
-8.61M
2024Q4
475
36.31M
66.90%
-8.91M
2024Q3
485
33.46M
61.86%
-11.26M
2024Q2
503
32.16M
60.76%
-21.31M
2024Q1
512
37.52M
71.59%
-17.68M
2023Q4
531
43.49M
83.79%
-11.00M
2023Q3
581
43.88M
84.66%
-15.71M
2023Q2
596
48.59M
93.79%
-8.52M
2023Q1
682
47.08M
93.36%
-12.05M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
3.21M
5.92%
+13.30K
+0.42%
Mar 31, 2025
Millennium Management LLC
2.50M
4.61%
+1.02M
+68.87%
Mar 31, 2025
American Century Investment Management, Inc.
2.30M
4.23%
+159.91K
+7.48%
Mar 31, 2025
State Street Global Advisors (US)
1.71M
3.15%
-253.01K
-12.88%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.60M
2.94%
+492.58K
+44.62%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.58M
2.92%
-61.06K
-3.71%
Mar 31, 2025
Marshall Wace LLP
1.16M
2.13%
-170.78K
-12.85%
Mar 31, 2025
Palisade Capital Management, LLC
1.14M
2.1%
+202.86K
+21.61%
Mar 31, 2025
Oak Hill Advisors, L.P.
1.11M
2.05%
--
--
Mar 31, 2025
Qube Research & Technologies Ltd
1.09M
2%
+271.55K
+33.29%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Harbor Human Capital Factor US Small Cap ETF
0.15%
Invesco RAFI US 1500 Small-Mid ETF
0.14%
SPDR S&P Biotech ETF
0.13%
Federated Hermes MDT Small Cap Core ETF
0.1%
Pacer US Small Cap Cash Cows ETF
0.09%
iShares Micro-Cap ETF
0.08%
Avantis US Small Cap Value ETF
0.08%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Avantis US Small Cap Equity ETF
0.04%
Mehr Anzeigen
Harbor Human Capital Factor US Small Cap ETF
Anteil0.15%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.14%
SPDR S&P Biotech ETF
Anteil0.13%
Federated Hermes MDT Small Cap Core ETF
Anteil0.1%
Pacer US Small Cap Cash Cows ETF
Anteil0.09%
iShares Micro-Cap ETF
Anteil0.08%
Avantis US Small Cap Value ETF
Anteil0.08%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.05%
Avantis US Small Cap Equity ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
